EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.

MLA

Zhao, Ruiying, et al. “EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-Small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.” Targeted Oncology, vol. 19, no. 2, Mar. 2024, pp. 277–88. EBSCOhost, https://doi.org/10.1007/s11523-024-01042-3.

APA

Zhao, R., Li, J., Guo, L., Xiang, C., Chen, S., Zhao, J., Shao, J., Zhu, L., Ye, M., Qin, G., Chu, T., & Han, Y. (2024). EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation. Targeted Oncology, 19(2), 277–288. https://doi.org/10.1007/s11523-024-01042-3

Chicago

Zhao, Ruiying, Jiaqi Li, Lianying Guo, Chan Xiang, Shengnan Chen, Jikai Zhao, Jinchen Shao, et al. 2024. “EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-Small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.” Targeted Oncology 19 (2): 277–88. doi:10.1007/s11523-024-01042-3.